Overview

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Status:
NOT_YET_RECRUITING

Trial end date:
2032-02-27

Target enrollment:

Participant gender:

Summary

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Collaborator:

Exelixis

Treatments:

belzutifan
cabozantinib